Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]-APN-1607 PET in AD-related Cognitive Impairment
NCT07422857Phase 3Recruiting
- Sponsor
- JYAMS PET Research & Development
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 3 trial of florzolotau in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by JYAMS PET Research & Development. Started Jan 2026; status: recruiting.
02
Drugs
florzolotau
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07422857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422857.